125 related articles for article (PubMed ID: 19432851)
21. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.
Solaro C; Bergamaschi R; Rezzani C; Mueller M; Trabucco E; Bargiggia V; Dematteis F; Mattioda A; Cimino V; Restivo D; Patti F; Cavalla P
Clin Neuropharmacol; 2013; 36(4):114-6. PubMed ID: 23783007
[TBL] [Abstract][Full Text] [Related]
22. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
[TBL] [Abstract][Full Text] [Related]
23. Bipolar disorder.
Grande I; Berk M; Birmaher B; Vieta E
Lancet; 2016 Apr; 387(10027):1561-1572. PubMed ID: 26388529
[TBL] [Abstract][Full Text] [Related]
24. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
25. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
Chong J; Karner C; Poole P
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
[TBL] [Abstract][Full Text] [Related]
26. Comparison of intravenous low molecular weight iron dextran and intravenous iron sucrose for the correction of anaemia in pre-dialysis chronic kidney disease patients: a randomized single-centre study in Nigeria.
Waziri B; Mabayoje M; Bello B
Clin Kidney J; 2016 Dec; 9(6):817-822. PubMed ID: 27994861
[TBL] [Abstract][Full Text] [Related]
27. Managing inadequate antidepressant response in depressive illness.
Haddad PM; Talbot PS; Anderson IM; McAllister-Williams RH
Br Med Bull; 2015 Sep; 115(1):183-201. PubMed ID: 26311502
[TBL] [Abstract][Full Text] [Related]
28. Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial.
Salim R; Garmi G; Nachum Z; Zafran N; Baram S; Shalev E
Obstet Gynecol; 2012 Dec; 120(6):1323-31. PubMed ID: 23168756
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients.
Loughnan A; Ali GR; Abeygunasekara SC
Ren Fail; 2011; 33(3):373-5. PubMed ID: 21401367
[TBL] [Abstract][Full Text] [Related]
30. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes.
Yohannes AM; Willgoss TG; Vestbo J
Respir Care; 2011 Apr; 56(4):477-87. PubMed ID: 21255503
[TBL] [Abstract][Full Text] [Related]
31. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties.
Storring PL; Tiplady RJ; Gaines Das RE; Stenning BE; Lamikanra A; Rafferty B; Lee J
Br J Haematol; 1998 Jan; 100(1):79-89. PubMed ID: 9450795
[TBL] [Abstract][Full Text] [Related]
32. Comparison of rates of reported adverse events associated with i.v. iron products in the United States.
Bailie GR
Am J Health Syst Pharm; 2012 Feb; 69(4):310-20. PubMed ID: 22302256
[TBL] [Abstract][Full Text] [Related]
33. Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
Albaramki J; Hodson EM; Craig JC; Webster AC
Cochrane Database Syst Rev; 2012 Jan; 1():CD007857. PubMed ID: 22258974
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY
Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled study of iron supplementation in patients treated with erythropoietin.
Macdougall IC; Tucker B; Thompson J; Tomson CR; Baker LR; Raine AE
Kidney Int; 1996 Nov; 50(5):1694-9. PubMed ID: 8914038
[TBL] [Abstract][Full Text] [Related]
36. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
Fishbane S; Frei GL; Maesaka J
Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject) and iron(III) hydroxide dextran (Cosmofer) in pregnancy.
Myers B; Myers O; Moore J
Obstet Med; 2012 Sep; 5(3):105-7. PubMed ID: 27582865
[TBL] [Abstract][Full Text] [Related]
38. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.
Rampton D; Folkersen J; Fishbane S; Hedenus M; Howaldt S; Locatelli F; Patni S; Szebeni J; Weiss G
Haematologica; 2014 Nov; 99(11):1671-6. PubMed ID: 25420283
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of Intravenous Iron Sucrose versus Low Molecular Weight Iron Dextran for Treatment of Iron Deficiency Anemia in Pregnancy: A Randomized Controlled Trial.
Samsudin S; Dulasi M; Sany S; Balanathan K; Chong SE; Ali A
Int J Womens Health; 2020; 12():1259-1270. PubMed ID: 33408531
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
